MedTrace Logo

Evaluation of Effectiveness of the Treatment After Repeated Administration of Klacid®SR

NCT01130883 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3130

Last updated 2025-10-06

Study results available
· View outcomes & findings →

Summary

This post-marketing observational study (PMOS) will be conducted in a prospective, single-arm, single-country, multicenter format. The investigational sites will be consulting rooms of GPs (general practitioner), pneumologists and centers with experience in the treatment of patients with acute infections of trachea, bronchi, AECB (acute exacerbation of chronic bronchitis) and CAP (mild community-acquired pneumonia). Since this will be a post-marketing observational study, Klacid SR will be prescribed in usual manner in accordance with the terms of the local market authorization with regards to dose, population and indication as well as local guidelines. Objective: to describe the effectiveness of the treatment with repeated administration of Klacid SR in patients with acute tracheitis, acute tracheobronchitis or acute bronchitis; or in patients with acute exacerbation of chronic bronchitis (AECB) or mild community-acquired pneumonia (CAP) who received Klacid SR treatment 6 weeks to 24 months prior to the Klacid SR dose administered within this study.

Conditions

  • Tracheitis
  • Tracheobronchitis
  • Bronchitis
  • Chronic Bronchitis
  • Community-Acquired Pneumonia (CAP)

Sponsors & Collaborators

Principal Investigators

  • Adam Hloska, M.D. · Abbott Laboratories, s.r.o. (Czech Republic)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01130883 on ClinicalTrials.gov